Intended for healthcare professionals


French to take legal action against drug regulator over levothyroxine

BMJ 2021; 374 doi: (Published 14 September 2021) Cite this as: BMJ 2021;374:n2243
  1. Barbara Casassus
  1. Paris, France

Hundreds of patients in France are expected to join a legal challenge against the country’s medicines agency in the latest attempt to obtain redress for the adverse side effects they experienced from Merck’s reformulated levothyroxine drug more than four years ago.

On 14 September lawyer Christophe Lèguevaques of MySMARTcab will launch the French equivalent of a class action suit against the National Agency for the Safety of Medicines and Health Products (ANSM) for failing to protect French patients from health risks because of the change. Most of the patients are women.

“We hope at least 1000 people will join the suit,” Lèguevaques told The BMJ. The investigating magistrate has received more than 10 000 complaints, he added. “If Merck is prosecuted, this could be …

View Full Text

Log in

Log in through your institution


* For online subscription